Eli Lilly and Company
LLY
Below: live stock price for Eli Lilly and Company (LLY), a 1-year chart, 8 indicators (RSI, MACD, Bollinger, MA, EMA, Stochastic, ATR, Volume), and a compare mode. Add to your portfolio, star to your watchlist, or set a price alert in one place.
Eli Lilly and Company (LLY) trades at 1,150.79 USD on investpig.
- Prev close
- $1,160.08
- Volume (24h)
- $393.51M
- Market cap
- $1.03T
- Currency
- USD
Score
Insufficient data
- Value—
- Quality—
- Momentum—
- Growth—
- Risk—
- Dividend—
- Liquidity—
Composite of public market data. Informational only — not investment advice.
Trend projection
Where the recent trend points if it continues.
- +5 bars
- 1,154.72 +0.34%
- +20 bars
- 1,160.13 +0.81%
- +60 bars
- 1,162.23 +0.99%
- +120 bars
- 1,162.31 +1.00%
Linear-regression continuation — not a prediction, not investment advice. ±1σ ≈ 68% range · ±2σ ≈ 95% range: ±0.0326 USD.
Interpretation
Price sits in the middle of the recent range, trend is roughly flat.
Descriptive observation — not investment advice.
Price report
How this asset has actually moved over the last 253 days.
Where the price sits between the window low and high.
- Volatility (annualised)
- 35.5%
- Max drawdown
- -23.3%
- Below period high
- -11.0%
- Best day
- +10.33%
- Worst day
- -7.79%
- Up days
- 50%
- Current streak
- 1 down
- Typical day swing
- 2.9%
- Volume vs average
- -16%
Spread of returns. Higher means larger swings in both directions.
Worst peak-to-trough fall inside the window.
Current price against the highest point in the window.
Share of days that closed above the one before.
Average high-to-low spread within a single day.
Last 10 days against the whole window.
Descriptive statistics over past prices — not a forecast and not investment advice.
Reference levels
Fibonacci retracements and extensions across the recent range.
Reference only — not investment advice.
These coordinates describe past-trade clustering, not where to buy or sell. Do your own research before any trade.
Levels derived from: 1,292.65 high → 1,079.22 low · 60 bars
- ResistanceFib +161.8% extensionnot reached1,637.98 USD+42.33% from current
- ResistanceFib +100% extensionnot reached1,506.08 USD+30.87% from current
- ResistanceFib +61.8% extensionnot reached1,424.55 USD+23.79% from current
- ResistanceFib +27.2% extensionnot reached1,350.7 USD+17.37% from current
- ResistanceFib 23.6% retracementtested 5×1,242.28 USD+7.95% from current
- ResistanceFib 38.2% retracementtested 19×1,211.12 USD+5.24% from current
- ResistanceFib 50% midpointtested 22×1,185.93 USD+3.05% from current
- ResistanceFib 61.8% retracementNearesttested 19×1,160.75 USD+0.86% from current
- Current1,150.82 USD
- SupportFib 78.6% retracementtested 7×1,124.89 USD-2.25% from current
- SupportFib −27.2% extensionnot reached1,021.17 USD-11.27% from current
- SupportFib −61.8% extensionnot reached947.3202 USD-17.68% from current
- SupportFib −100% extensionnot reached865.7899 USD-24.77% from current
How to read this
We take the highest and lowest price of the last 60 bars and cut the gap between them at the classic Fibonacci ratios (23.6%, 38.2%, 50%, 61.8%, 78.6%), plus extensions beyond both ends.
“Tested N×” counts how many of those 60 bars actually traded through the level. A level price has crossed many times is one the market has repeatedly agreed on; a level at 0 is pure geometry the price has never reached.
This is a map of where trading has already happened — not a forecast and not a signal. Price moves through these levels all the time.
Recent news
- Eli Lilly Unit to Make $8.6 Million Milestone Payment to Nxera PharmaMT Newswires5h ago
- Rothschild & Co Redburn Adjusts PT on Eli Lilly and Co. to $930 From $915, Keeps Neutral RatingMT Newswires4h ago
- Can LLY's Merida Deal Boost Its M&A Push to Diversify Beyond GLP-1s?Zacks23h ago
- Superluminal Medicines Announces Oversubscribed $60 Million Series B Financing to Advance Lead Program in Rare Genetic Forms of Obesity into the ClinicPR Newswire3h ago
- Eli Lilly Just Announced a Major Acquisition. Here's What It Means.Motley Fool17h ago
- Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development ProgressGlobeNewswire7h ago
- Lilly’s Record Stock Price Is Hiding an Even Bigger Opportunity24/7 Wall St.21h ago
- Wegovy’s German Debut Opens a New Front for Novo Nordisk (NVO)Insider Monkey12h ago
Related
Other assets in this category.
- 8306.TMitsubishi UFJ Financial Group, Inc.3,754 USD+1.90%
- 7203.TToyota Motor Corporation3,117 USD-0.51%
- 9984.TSoftBank Group Corp.5,001 USD+1.56%
- 6758.TSony Group Corporation3,895 USD-0.64%
- 6861.TKeyence Corporation77,980 USD-0.05%
- NVDANVIDIA Corporation227.8706 USD+1.54%
- AAPLApple Inc.326.345 USD+0.43%
- GOOGLAlphabet Inc.342.64 USD+1.64%
Live discussion
Sign in to join the discussion.
- No comments yet. Be the first.